



HINDUSTAN FOODS LIMITED

A Vanity Case Group Company

A Government Recognised Star Export House

Registered Office: Office No. 3, Level 2, Centrium, Phoenix Market City,
15, Lal Bahadur Shastri Road, Kurla (West), Mumbai, Maharashtra, India, 400 070.

Email: business@thevanitycase.com, **Website:** www.hindustanfoodslimited.com

Tel. No.: +91 22 6980 1700/01, **CIN:** L15139MH1984PLC316003

Company Scrip Code: 519126

Date: February 8, 2023

To,
The General Manager
Department of Corporate Services
BSE Limited
Floor 25, P. J. Towers, Dalal Street,
Mumbai-400 001.
Tel : (022) 2272 1233 / 34

Through Listing Centre

Dear Sir/Madam,

Subject: Earnings Presentation February 2023

In pursuance to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 please find attached herewith the “Earnings Presentation February 2023” for Quarter and Nine Months ended December 31, 2022.

We request you to take above on record.

Thanking you.

Yours faithfully,
For **Hindustan Foods Limited**

Bankim Purohit
Company Secretary
ACS: 21865

Encl. As above





Hindustan Foods Limited

EARNINGS PRESENTATION **FEBRUARY 2023**



This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Hindustan Foods Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company

This Presentation is not a prospectus, disclosure document, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, and the rules made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This Presentation should not be considered as a recommendation that any investor should subscribe for or purchase any securities of the Company or its subsidiary and should not be used as a basis for any investment decision. The information contained in this Presentation is only current as of its date and has not been independently verified. The Company will not update you in the event the information in the Presentation becomes stale. Moreover, both express or implied representation or warranty is made as to, and no reliance should be placed on, the truth, accuracy, fairness, reasonableness or completeness of the information presented or contained in this Presentation and nothing in this Presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.



Uttar Pradesh | Ice Cream Plant



**Gross Block for 9MFY23 includes wholly owned subsidiaries/LLP and includes CWIP

*PAT includes, excess provision of tax to the tune of Rs. 1.8 Crores in FY 22 which was reversed in FY 23 after filing tax returns

Includes other income

The Company recently executed a Business Transfer Agreement for acquisition of a pharmaceutical factory from Reckitt Benckiser further expanding its Health Care, OTC Medicines & Wellness Division

The Ice Cream facility in Lucknow, Uttar Pradesh set up by the wholly owned subsidiary of the Company has commenced operations and the expanded capacity is also expected to be operational from March '23.

The Company's capex plans for setting up the Soap Bar project continue to progress and is expected to commercialize by Q1FY24

Acquisition Of Manufacturing Facility Of Reckitt Benckiser



Baddi | OTC Medicine & Skin Care

Details About The Acquisition

Overview

- **Hindustan Foods Limited** has executed Business Transfer Agreement for acquisition of Reckitt Benckiser Healthcare India Private Limited's manufacturing facility as a move to further expand its Health Care & Wellness division
- The manufacturing facility is located in Baddi, Himachal Pradesh and it manufactures a vast variety of pharmaceutical, non-pharmaceutical and wellness products . It is a state-of-the-art Facility with modern machinery & at par with global standards.

Key Highlights Of The Facility

Experienced team
as a part of
transaction

India's prime
manufacturing hub

Highest quality &
standards

Cutting Edge
manufacturing
setup

Extensive range of
pharma products

Future growth for
international
clients

Product profile

Machinery capable of producing wide producing range of products-



Ointment & Creams



Strips



Liquid syrups



Liquid Handwash



Plaster



Tablets

The company is acquiring the facility on going concern basis and expects to enter into a long term supply agreement.

Consideration

- It is proposed that the undertaking will be acquired for a cash consideration INR 156 Cr, subject to certain adjustment on closing date in accordance to conditions set out in the BTA

Rationale

Long Term Production Commitment

- The company expects to enter into a long term supply agreement as per mutually agreed terms.
- This long term production commitment will lead to a minimum capacity utilization and also allow the company to offer the idle capacity to other customers..

Idle Capacity utilized to service new clients

- Ample unutilized capacity available at the facility to cater to additional domestic/ global clients.
- Idle capacity can be leveraged to external sources which could reap benefits like-



Increased Clientele



Better Asset Sweating



Higher Revenue



Increased profit & RoCE

Opportunity to cater new clients

- Presence of leading global certifications allow the Facility to manufacture multiple products for international use.
- Manufacturing a wide range of products-



Allopathic Liquids



Ayurvedic Ointments & Creams



Lozenge



Personal Care Plasters



Commenting on the Results, Mr. Sameer R. Kothari, Managing Director said, “I am pleased with the overall performance of the company in the last 9 months and ramp up of the ice cream facility and beverage facility in the last quarter of this year should help us close the year with record turnover. This in spite of the tepid FMCG demand in the last few quarters is a testament to the resilience of our business model and gives us confidence that as volume growth returns to the FMCG industry, we will be able to leverage it further.

With the acquisition of the Chennai Scholl factory and the planned acquisition of the Baddi factory, we are well poised to serve the customers in the OTC Pharma and Wellness segment. These acquisitions of US FDA and MHRA approved factories give us a strong footprint in this segment along with the comfort of assured volumes from our existing customers. These facilities will also enable us to tap some new customers including high-end skin care and wellness brands.

After the expansion of the Ice Cream project in Lucknow (slated to start commercial production in March '23), we will now be amongst the largest manufacturers of ice cream in the country and are looking forward to expanding in this area.

I am confident that our earlier goal of INR 4,000 crores turnover by FY 25 will be revised upwards in view of these developments.”




Commenting on the Results, Mr. Mayank Samdani, Group CFO said, “Our turnover for the quarter on a consolidated basis has increased by 29% YoY while the PAT rose by 46% YoY. The QoQ revenue numbers were flattish as it was the lean season for both beverages and ice cream and the QoQ numbers for PAT are strictly not comparable as the last quarter PAT numbers were buoyed by a one-time tax write back arising due to our acquisition.


Our revenues for the 9MFY23 are highest ever and our PAT for the 9 month period is higher than that of the entire past year. We expect our MAT credit to be utilized in this year and will accordingly explore the possibility of moving to a lower tax rate under the new regime by next year”

Q3 FY23 Consolidated Result Highlights


Revenue# (Rs. Crs.)




EBITDA (Rs. Crs.)



Profit before Tax (Rs. Crs.)



Profit after Tax (Rs. Crs.)




Includes Other Income


Note: Q3FY22 numbers are restated

9M FY23 Consolidated Result Highlights


Revenue# (Rs. Crs.)




EBITDA (Rs. Crs.)



Profit before Tax (Rs. Crs.)



Profit after Tax* (Rs. Crs.)



Includes Other Income

*PAT includes, excess provision of tax to the tune of Rs. 1.8 Crores in FY 22 which was reversed in FY 23 after filing tax returns

Note: 9MFY22 numbers are restated

Consolidated Profit & Loss Statement – Q3 & 9M FY23



Particulars (Rs. Crs.)	Q3 FY23	Q3 FY22	Y-o-Y	Q2 FY23	Q-o-Q	9M FY23	9M FY22	Y-o-Y
Total Revenue#	679.6	527.8	28.8%	663.7	2.4%	1,941.9	1,461.2	32.9%
Cost of Goods Sold	586.5	460.5		572.9		1,675.1	1,267.6	
Manufacturing and Operating Costs	25.8	20.6		25.3		76.2	58.4	
Gross Profit	67.4	46.7	44.3%	65.4	3.0%	190.6	135.2	40.9%
Employee Expenses	14.3	10.0		13.5		39.7	29.5	
Other Expenses	8.1	6.7		7.8		23.2	19.2	
EBITDA	45.0	30.0	50.0%	44.0	2.2%	127.7	86.5	47.6%
Depreciation	10.0	6.1		9.5		28.1	17.5	
EBIT	35.1	23.9		34.5		99.6	69.0	
Finance Cost	9.8	5.3		9.1		26.1	15.4	
Share of Loss from JV	0.0	0.0		0.0		0.0	-1.5	
Profit Before Tax	25.3	18.5	36.8%	25.4	-0.2%	73.5	52.1	41.0%
Tax expense for current year	8.2	6.8		8.2		24.5	19.5	
Adj. Profit After Tax	17.1	11.7	46.2%	17.1	-0.3%	49.1	32.7	50.2%
Tax adjustments for previous year	0.0	0.0		1.8		1.8	0.0	
Profit After Tax	17.1	11.7	46.2%	18.9	-9.8%	50.9	32.7	55.8%
EPS^	1.51	1.04		1.68		4.51	2.90	

Includes Other Income ^ EPS numbers are restated

Note: Q3FY22 & 9MFY22 numbers are restated

Uttar Pradesh: Ice Cream (Rs. 125 cr + Rs. 75 Cr)

- The Phase 1 of the Uttar Pradesh Ice Cream Project has commenced commercial production
- The Rs 75 crore expansion sanctioned by the Board earlier is expected to be commercialized by March '23
- Production from the unit is expected to be ramped up to 20,000,000 liters of ice cream by the end of FY23

Hyderabad: Bath Soaps & Detergent Bars (Rs. 125 cr)

- The Project work is progressing well and the Management expects commercial production by Q1FY24

Healthcare & Wellness (Rs. 100 cr + Rs. 156 Cr)

- The company has successfully completed the acquisition and has integrated the same successfully,
- The company has also announced another acquisition in this space

Progress against Deliverables

- **HFL**, along with BAIF Institute for Sustainable Livelihoods and Development, has identified **Peddaipally, Khethireddypally** and **Balanagar** villages in the Mahbubnagar District, Telangana to pilot a '*village development program*' to enhance education and health.
- The project will focus on providing basic facilities in government schools like construction of toilets, midday meals shed, kitchen renovation, solar street-lights, computers, printers & projectors, and other primary infrastructure.
- The project will also emphasize on health & hygiene awareness.
- **Project amount: Rs 18 Lakhs**
- **Project Duration: 1st August 2022- 31st March 2023**



THANK YOU

Company:



Hindustan Foods Limited

CIN: L15139MH1984PLC316003

Vimal Solanki

vimal.solanki@thevanitycase.com

www.hindustanfoodslimited.com

Investor Relations Advisors:



Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Rahul Agarwal / Brinkle Shah Jariwala

rahul.agarwal@sgapl.net / Brinkle.shah@sgapl.net

+91 9821438864 / +91 9619385544

www.sgapl.net